Introduction
============

Cervical cancer is the fourth most common type of cancer among women worldwide, with 527,600 estimated new cases in 2012 ([@b1-ijo-50-06-1947]). Infection with the human papillomavirus (HPV) has been established to be a necessary cause of invasive cervical cancer ([@b2-ijo-50-06-1947]--[@b4-ijo-50-06-1947]). The lifetime risk of acquiring an HPV infection is \~80% among sexually active women, but most women clear the virus uneventfully ([@b5-ijo-50-06-1947]). When infection with HPV persists, this can lead to malignant cellular changes ranging from cervical intraepithelial neoplasia (CIN)1, CIN2 and CIN3 to invasive cervical cancer. Persistent HPV infections have been associated with chronic inflammation, with large numbers of inflammatory cells often surrounding cervical cancer cells ([@b6-ijo-50-06-1947]). Macrophages are a major component of cancer-related inflammation, and they are roughly divided into two main subgroups: the classically activated type 1 macrophages (M1), which are pro-inflammatory (enhanced expression and release of TNF-α, IL-6, IL-12), and the alternative activated type 2 macrophages (M2), which show anti-inflammatory properties (enhanced expression and release of TGF-β1, IL-10, prostaglandin E2) ([@b6-ijo-50-06-1947]--[@b11-ijo-50-06-1947]). Tumors mediate the accumulation and differentiation of macrophages to sustain tumor growth, and increased numbers of tumor-associated macrophages (TAM) are associated with disease progression and poor prognosis in cervical cancer ([@b12-ijo-50-06-1947]--[@b14-ijo-50-06-1947]).

In cervical cancer, high expression of the epidermal growth factor receptor (EGFR) is associated with tumor development, as EGFR expression increases with increasing malignant stage and subsequent EGFR activation leads to cell growth, differentiation, resistance to apoptosis, cell cycle progression and angiogenesis. EGFR-based therapy has established efficacy in selected patients with head and neck squamous cell carcinoma, colorectal carcinoma and non-small cell lung carcinoma ([@b15-ijo-50-06-1947]--[@b17-ijo-50-06-1947]). It is currently being explored as a therapeutic target in cervical cancer, as EGFR expression is overexpressed in 70--90% of the cases and has been associated with poor prognosis ([@b17-ijo-50-06-1947]--[@b22-ijo-50-06-1947]).

Cell line studies and mouse models show that TAM aid tumor progression through a paracrine loop with EGFR. EGFR activation regulates the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF/CFS2) by tumor cells, thus attracting macrophages to EGFR-expressing tumors where these macrophages express and release EGFR ligands, leading to EGFR activation and subsequent tumor cell proliferation ([@b23-ijo-50-06-1947]--[@b29-ijo-50-06-1947]). Although \~70% of cervical cancers show increased EGFR expression, and high EGFR expression is associated with decreased disease-specific survival, this paracrine loop has never been investigated in human cervical cancer ([@b18-ijo-50-06-1947],[@b30-ijo-50-06-1947]--[@b32-ijo-50-06-1947]).

We hypothesized that macrophages are the main source of EGFR ligands and that a paracrine loop between tumor cells and macrophages is responsible for ligand expression. First, we investigated whether macrophages are the predominant source of EGFR ligands in human cervical cancer. Therefore, we first assessed which of the known EGFR ligands was present in cervical cancer specimens and which ligand was associated with EGFR expression. Subsequently, we tested whether this ligand was predominantly expressed by TAM. Finally we determined whether an association could be found between EGFR expression by cervical cancer cells and the number of cells expressing the EGFR ligand.

Materials and methods
=====================

Tissue samples
--------------

All tissue samples were collected from the archives of the Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. Only material from cervical cancer patients who underwent radical hysterectomy with lymphadenectomy between 1985 and 1995, had not received radiotherapy or chemotherapy prior to surgery, had a histopathological diagnosis of squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma and had enough primary tumor material available was used. For mRNA expression analysis of amphiregulin (AREG), β-cellulin, epidermal growth factor (EGF), epiregulin, heparin-binding EGF-like growth factor (HB-EGF), transforming growth factor a (TGFα) and EGFR, 32 frozen cervical cancer tissue samples were collected. For immunohistochemistry and mRNA *in situ* hybridization, 36 formalin-fixed, paraffin-embedded cervical cancer tissue samples were collected. The group of 32 frozen cervical cancer specimens did not overlap with the group of 36 formalin-fixed, paraffin-embedded cervical cancer specimens. Tissue samples were used according to the guidelines of the Ethical Committee of the Leiden University Medical Center.

mRNA expression analysis
------------------------

mRNA extraction and analysis of microarray expression data were performed as previously described ([@b33-ijo-50-06-1947]). In short, mRNA was obtained from 32 frozen cervical squamous cell carcinoma tissue samples, using TRIzol (Life Technologies, Carlsbad, CA, USA). mRNA was subsequently purified, after which cDNA was synthesized and transcribed into cRNA using the Illumina Totalprep RNA amplification kit following the manufacturer\'s instructions (Ambion, Austin, Tx, USA). Labeled cRNA was hybridized to Illumina Sentrix-human 6 expression bead-chips. Gene expression levels were quantified using beadstudio gene expression module 2.1, and data were subsequently normalized using the VSN method ([@b34-ijo-50-06-1947]).

Immunohistochemistry
--------------------

Four-micrometre tissue sections were deparaffinized, rehydrated, and endogenous peroxidase was blocked with 0.3% hydrogen peroxide (H~2~O~2~) for 20 min. For HB-EGF, AREG and TGFα, antigen retrieval was performed in 0.01 M citrate buffer (pH 6.0, 12 min). Subsequently, slides were incubated overnight with polyclonal goat anti-human HB-EGF (1:200 at 4°C, af-259-na, R&D Systems Europe Ltd., Abingdon, UK), polyclonal goat anti-human AREG (1:100, af-262, R&D Systems) and mouse monoclonal anti-human TGFα (1:50, clone P/T1, Abcam, Cambridge, UK) diluted in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA). After washing with PBS, tissue sections were incubated with a goat probe and anti-goat horseradish peroxidase (HRP) according to the manufacturer\'s instructions (Goat HRP-polymer kit, GHP516, Biocare Medical, Concord, CA, USA) for AREG and HB-EGF. Tissue sections were incubated with anti-TGFα with BrightVision-Poly/HRP (Immunologic, Duiven, The Netherlands). Immunoreactions were visualized using a 3.3′-diaminobenzidine-tetrahydrochloryde (DAB)^+^ chromogen (Dako, Heverlee, Belgium), and counterstained with hematoxylin. The results were scored for tumor compartment staining intensity \[negative (0), weak ([@b1-ijo-50-06-1947]), moderate ([@b2-ijo-50-06-1947]) or strong ([@b3-ijo-50-06-1947])\] and for the presence of ligand positive cells in the stroma (positive or negative).

EGFR protein expression was determined as previously described ([@b18-ijo-50-06-1947]). The intensity of EGFR membrane staining was scored as negative (0), weak ([@b1-ijo-50-06-1947]), moderate ([@b2-ijo-50-06-1947]) or strong ([@b3-ijo-50-06-1947]). Strong immunoreactivity was defined as complete membrane staining, producing a thick outline of the cell. Presence of TAM was determined though immunohistochemical staining of CD68 as previously described ([@b25-ijo-50-06-1947]). The total number of TAM in the tumor and stromal compartment was quantified by counting the number of positive cells per six, randomly selected, high-power fields of view.

For immunohistochemical double staining for CD68 and HB-EGF, four representative tissue slides were deparaffinized, rehydrated, and endogenous peroxidase was blocked with 0.3% H~2~O~2~ for 20 min. Antigen retrieval was performed with 0.01 M citrate buffer, and slides were incubated overnight with anti-HB-EGF and mouse monoclonal anti-human CD68 (1:50, 514H12, AbD Serotec, Oxford, Uk) diluted in Tris(hydroxymethyl)aminomethane buffered saline (TBS) containing 1% BSA. After washing with TBS, tissue sections were first incubated with a goat probe, subsequent anti-goat HRP and DAB^+^ to visualize HB-EGF. Then, to visualize CD68, tissue slides were incubated with an alkaline phosphatase (AP)-labeled secondary antibody (1:200, rabbit anti-mouse IgG2a-AP, Southern Biotech, Uithoorn, The Netherlands) and subsequent PermaBlue (Diagnostic Biosystems, Uithoorn, The Netherlands) according to the manufacturer\'s instructions. No counterstaining was applied. For corresponding single staining of CD68 and HB-EGF the same protocol was used, but only one of the two primary antibodies was applied.

Analysis of immunohistochemically stained slides
------------------------------------------------

The number of CD68 and HB-EGF double positive cells was assessed using spectral imaging ([@b35-ijo-50-06-1947]). In short, five representative spectral images, containing both CD68 and HB-EGF-positive cells, were taken for each tissue specimen with a Leica DM4000 B microscope, equipped with a Nuance FX Multispectral Imaging System. The spectral libraries were created from PermaBlue and DAB single staining, after which spectral images from double stained tissue slides were acquired at the same wavelengths. The obtained spectral images were analyzed using Nuance software version 2.10, allowing unmixing into monochrome PermaBlue and DAB images. Subsequently, a simulated fluorescence composite image was created, after which the appropriate threshold for analysis was determined and the percentage of pixel-based co-localization was calculated for each image.

To measure the HB-EGF expression in the epithelial and stromal compartment, the single stained tissue slides were scanned, using the Pannoramic 250 Flash digital slide scanner (3DHistech), after which five representative images, containing both tumor and HB-EGF-positive stromal cells, were taken from each digitalized slide. Color deconvolution was applied to assess the staining intensity of HB-EGF (DAB) only and not the counterstaining (hematoxylin). The average staining intensity \[gray scale range: 0 (black) -- 255 (white)\] was assessed in a standardized area size (42×42 *μ*m) in three representative parts of the tumor. All measured staining intensities were subsequently inverted as follows for all measurements: 255 - measured staining intensity. Since HB-EGF expression was homogeneous in the tumor compartment (all tumor cells expressed HB-EGF equally), an average of three measured areas was used as a standardized measure to determine the relative HB-EGF amount in the tumor compartment. In the stromal compartment, single cells were positive for HB-EGF. Therefore, first, the staining intensity was determined for three separate DAB-positive cells in the stroma, after which the average of these three measurements was calculated. Then, the percentage of positive cells in the stroma was determined for each image, using the same threshold settings for all analyses. The average signal intensity was multiplied by the percentage of positive cells, to obtain a standardized measure for the relative HB-EGF amount in the stroma. One image was analyzed per slide, as the measurements proved to be consistent. The analyses were performed using ImageJ (version 1.45s, National Institutes of Health, MD, USA, freely available on <http://imagej.nih.gov/ij>).

mRNA in situ hybridization
--------------------------

Expression of the chemokines GM-CSF and CCL2 was determined by mRNA *in situ* hybridization as previously described and scored for staining intensity \[negative (0), weak ([@b1-ijo-50-06-1947]), moderate ([@b2-ijo-50-06-1947]) and strong ([@b3-ijo-50-06-1947])\] as well as percentage of tumor cells positive for chemokine expression \[1--5% ([@b1-ijo-50-06-1947]), 6--25% ([@b2-ijo-50-06-1947]), 26--50% ([@b3-ijo-50-06-1947]), 51--75% ([@b4-ijo-50-06-1947]) and 76--100% ([@b5-ijo-50-06-1947])\]. The sum of the staining intensity score and the percentage of positive cells resulted in an overall score for mRNA expression by tumor cells of either 0 or 2--8, which was then dichotomized into low (0--5) and high expression ([@b6-ijo-50-06-1947]--[@b8-ijo-50-06-1947]) ([@b24-ijo-50-06-1947],[@b25-ijo-50-06-1947]).

Statistical analysis
--------------------

Statistical analyses were performed using the SPSS program (Version 17.0 for Windows; SPSS Inc. Chicago, Ill, USA). Significance tests were two-sided and statistical significance was assumed when P\<0.05, corresponding to 95% confidence intervals (CI). For correlation analysis, the Spearman\'s correlation coefficient (ϱ, rho) was determined using ungrouped mRNA or protein expression scores. For crosstab analyses, odds ratios (OR) were calculated and the Fisher\'s exact test was used for calculation of P-values. In case of empty cells, 0.5 was added to each cell for OR calculation.

Results
=======

Expression of HB-EGF in cervical cancer
---------------------------------------

To assess which EGFR ligands are expressed in cervical cancer specimens, a genome-wide mRNA expression array of 32 cervical cancer specimens was analyzed for mRNA expression of EGFR and EGFR ligands. Median normalized mRNA expression was found to be substantial for *AREG, HB-EGF, TGFα* and *EGFR*, while expression of *EGF, β-cellulin* and *epiregulin* was low or absent ([Table I](#tI-ijo-50-06-1947){ref-type="table"}). To assess protein expression of HB-EGF, AREG and TGFα in cervical cancer and to determine the primary site of ligand expression, immunohistochemistry was performed on 36 specimens. Expression of all three ligands was observed in both the tumor and stromal compartment ([Table II](#tII-ijo-50-06-1947){ref-type="table"}). Representative examples of positive tumor compartment staining are shown in [Fig. 1](#f1-ijo-50-06-1947){ref-type="fig"}. The correlation between EGFR ligand expression and EGFR expression was determined, to assess which ligand is most likely the primary EGFR ligand in cervical cancer and whether this ligand was primarily expressed in the epithelial or stromal compartment ([Table III](#tIII-ijo-50-06-1947){ref-type="table"}). Both stromal compartment (ϱ=0.58, P\<0.001) and tumor compartment HB-EGF expression (ϱ=0.33, P=0.049) were correlated to EGFR expression. No correlations were observed between EGFR and AREG or TGFα.

Association between intensity of EGFR expression, number of TAM and expression of chemotactic factors by tumor cells
--------------------------------------------------------------------------------------------------------------------

Next, we assessed the correlation between EGFR expression and the number of CD68-positive TAM (cluster of differentiation 68, membrane glycoprotein that binds low density lipoprotein, a marker predominantly expressed by monocytes/macrophages). High EGFR expression was correlated to a high number of stromal TAM (ϱ=0.56, P\<0.001) and a high number of TAM in the tumor compartment (ϱ=0.43, P=0.009, [Table III](#tIII-ijo-50-06-1947){ref-type="table"}). To assess whether EGFR expression was associated with macrophage recruitment, the association between CD68^+^ TAM, EGFR, *M-CSF, GM-CSF* and *CCL2* expression by cervical cancer cells was determined. First, the Spearman\'s correlation between mRNA expression of *CD68* and *M-CSF, GM-CSF, CCL2* and their receptors *M-CSFR, GM-CFSR* and *CCR* was determined. CD68 was correlated with *M-CSFR* (P=0.003) and *CCR2* (P=0.018). However, *EGFR* was not associated with *M-CSF, GM-CSF, CCL2, M-CSFR, GM-CFSR* or *CCR.* Next, *GM-CSF* and *CCL2* mRNA expression, assessed through mRNA *in situ* hybridization was divided into low expression (combined intensity and percentage scores 0--5) and high expression (combined intensity and percentage scores 6--8). EGFR expression was divided into low (0--1) and high ([@b2-ijo-50-06-1947]--[@b3-ijo-50-06-1947]) intensity scores. High EGFR expression was associated with high *GM-CSF* and *CCL2* expression (OR, 11; P=0.039 and OR, 16; P=0.006, respectively).

Expression of HB-EGF in tumor-associated macrophages
----------------------------------------------------

We further investigated whether TAM could be an important source of HB-EGF in cervical cancer. Therefore, the correlation between HB-EGF expression and the number of TAM was determined. Stromal HB-EGF expression was positively correlated to the number of stromal TAM (ϱ=0.34, P=0.044), but no correlation was observed between tumor HB-EGF expression and the number of TAM in the tumor compartment (ϱ=0.24, P=0.163). To investigate whether the observed HB-EGF-positive cells in the stroma were indeed macrophages, immunohistochemical double staining was performed for CD68 and HB-EGF. CD68 and HB-EGF-double-positive cells were observed, i.e., the cervical cancer specimens showed macrophages expressing HB-EGF ([Fig. 2](#f2-ijo-50-06-1947){ref-type="fig"}), but analysis using spectral imaging showed that a subset of 4--14% of all observed macrophages expressed HB-EGF, with a mean of 9%. Furthermore, the majority of HB-EGF-positive cells in the stroma were CD68-negative, most likely fibroblasts or B-cells, suggesting that macrophages are not the predominant stromal source of HB-EGF in cervical cancer.

HB-EGF is expressed on tumor cells
----------------------------------

Immunohistochemical staining showed high HB-EGF expression in 78% of the cervical tumor specimens, suggesting that HB-EGF is utilized in an autocrine manner. [Fig. 3](#f3-ijo-50-06-1947){ref-type="fig"} shows a representative example of HB-EGF staining and EGFR staining within the same tumor specimen. To estimate the amount of HB-EGF in the tumor and stromal compartment, we measured the HB-EGF staining intensity in the cervical cancer samples, and adjusted the HB-EGF staining intensity for the number of HB-EGF-positive cells in the stroma and the epithelial compartment (relative HB-EGF amount). The average staining intensities as determined using ImageJ corresponded to the previously appointed immunohistochemical (weak, moderate or strong) intensity scores (data not shown). Subsequently, the relative HB-EGF expression in the tumor and stromal compartment was determined in each tissue slide. All individual relative HB-EGF amount ratios (epithelial cancer cells/stromal cells) were \>1, except for 2 cases (N=36), suggesting that even in cases with weak HB-EGF expression in the tumor compartment, the tumor compartment showed higher expression of HB-EGF than the stromal compartment ([Fig. 4](#f4-ijo-50-06-1947){ref-type="fig"}).

Discussion
==========

In this study, we investigated which EGFR ligands are expressed in cervical cancer and whether macrophages are the predominant source of these EGFR ligands. The results obtained suggest HB-EGF as the predominant EGFR ligand. Although EGFR expression is associated with macrophage counts and the expression of *CCL2* and *GM-CSF*, and macrophage numbers are associated with the expression of M-CSFR and CCR2, macrophages do not appear to be the predominant source of HB-EGF since the relative amount of HB-EGF measured in the epithelial compartment was on average four times higher than the relative amount of HB-EGF in the stromal compartment. These results suggest that, in cervical cancer, the tumor cells are the major source of HB-EGF.

mRNA expression analysis showed that three EGFR ligands were expressed in cervical cancer tissue, namely *HB-EGF, AREG* and *TGFα.* In previous studies in pancreatic cancer, where mRNA transcription of several EGFR ligands was observed, only HB-EGF was shown to be of significance at protein level ([@b36-ijo-50-06-1947]). To substantiate the findings on mRNA level in our study, we performed immunohistochemical staining on an independent group of cervical cancer patients, to determine protein expression of HB-EGF, AREG and TGFα. All three ligands were strongly expressed both in tumor stroma and in the epithelial compartment. However, only HB-EGF expression was associated with EGFR expression on the tumor cell membrane, indicating HB-EGF as the primary ligand for EGFR in cervical cancer.

Pollard ([@b32-ijo-50-06-1947]) and Vlaicu *et al* ([@b37-ijo-50-06-1947]), have shown through cell line research and mouse models, that in breast cancer, macrophage production of EGF induces EGFR activation on tumor cells, which in turn leads to M-CSF (CSF-1) production, consequently attracting more macrophages. M-CSF and its receptor have been shown to be upregulated in cervical cancer both on the mRNA and protein level, when compared to normal cervical tissue ([@b38-ijo-50-06-1947]). In turn, the inhibition of M-CSF prevents tumor progression in a cervical cancer mouse model ([@b39-ijo-50-06-1947]). In cervical cancer HeLa cells and macrophages, an analogous paracrine loop has been described with GM-CSF and HB-EGF expression ([@b26-ijo-50-06-1947],[@b27-ijo-50-06-1947]). In addition to cervical cancer cell lines, HB-EGF, AREG and TGFα expression and EGFR activation have previously been shown to induce GM-CSF release in several human cell lines, such as airway epithelial cells, keratinocytes and colon adenocarcinoma cells (DLD-1) ([@b27-ijo-50-06-1947],[@b28-ijo-50-06-1947],[@b40-ijo-50-06-1947]). The present study analyzed whether this interdependent paracrine signaling between tumor cells and macrophages through HB-EGF and GM-CSF was present in human cervical cancer. We observed that EGFR expression was associated with high numbers of TAM in the tumor and stromal compartment, and with high *GM-CSF* and *CCL2* expression. Previously, increased EGFR expression has been shown to downregulate CCL2, while EGFR inhibition has been shown to upregulate CCL2 expression *in vitro* in head and neck squamous cell carcinoma and primary cultures of normal human keratinocytes ([@b41-ijo-50-06-1947],[@b42-ijo-50-06-1947]). Only in osteoblasts and vascular smooth muscle cells has EGFR activation been shown to increase CCL2 expression ([@b43-ijo-50-06-1947],[@b44-ijo-50-06-1947]). Our results are concordant with the findings that EGFR expression is associated with GM-CSF and CCL2 expression by tumor cells, thus attracting macrophages to the tumor site. However, although EGFR expression was associated with macrophage recruitment, double staining for CD68 and HB-EGF showed that only a limited number (9%) of the macrophages were HB-EGF-positive. Furthermore, only a small proportion of HB-EGF-positive cells in the stroma was CD68-positive, as fibroblasts and B-cells also appeared to be HB-EGF-positive, suggesting that macrophages are not the predominant source of HB-EGF in cervical cancer stroma.

It has been suggested that HB-EGF is expressed by cervical cancer-associated stromal fibroblasts, thus promoting cancer cell proliferation in a paracrine manner ([@b45-ijo-50-06-1947]). However, although our study showed that tumor stroma was indeed positive for HB-EGF, the largest relative amount of HB-EGF was detected in the cytoplasm of cervical cancer cells, as the relative amount of HB-EGF in the epithelial compartment exceeded the relative amount of HB-EGF in the stromal compartment by a factor of four. Thus, we conclude that HB-EGF is expressed in an autocrine manner in cervical cancer. *In vitro* experiments with head and neck squamous cell carcinoma cells show that this HB-EGF autocrine loop is associated with invasive processes through the EGFR-Src-cortactin cascade ([@b46-ijo-50-06-1947]).

Based on our results, we propose an autocrine EGFR stimulation model in cervical carcinoma, with cervical cancer cells being the predominant source of HB-EGF. Cervical cancer cells are shown to express GM-CSF to attract macrophages to the tumor environment. Although macrophages and other stromal cells express the primary EGFR ligand HB-EGF, they do not appear to be the major source of HB-EGF, as the relative amount of HB-EGF measured in the tumor cell compartment was on average four times higher than the relative amount of HB-EGF in the stromal compartment. The proposed autocrine mechanism of HB-EGF expression is shown in [Fig. 5](#f5-ijo-50-06-1947){ref-type="fig"}.
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![Representative examples of heparin-binding EGF-like growth factor \[(HB-EGF); (A) strong, (B) weak\], amphiregulin \[(AREG)/0; (C) strong, (D) weak\] and transforming growth factor-α staining \[(TGFα); (E) strong, (F) weak)\] immunohistochemical staining in the epithelial compartment (asterisk) of squamous cell carcinoma of the cervix.](IJO-50-06-1947-g00){#f1-ijo-50-06-1947}

![Immunohistochemical double staining of heparin-binding EGF-like growth factor (HB-EGF, DAB) and macrophages (CD68, PermaBlue), without nuclear counterstaining (A), and the simulated fluorescence composite image obtained through spectral imaging (B), showing not only macrophages (arrow), but also other cells in the stroma and tumor cells strongly expressing HB-EGF in cervical cancer.](IJO-50-06-1947-g01){#f2-ijo-50-06-1947}

![Representative example of epidermal growth factor receptor (EGFR) (A) and heparin-binding EGF-like growth factor (HB-EGF) (B) immunohistochemical staining within the same squamous cell carcinoma tumor specimen, showing membranous staining of EGFR and cytoplasmic staining of HB-EGF.](IJO-50-06-1947-g02){#f3-ijo-50-06-1947}

![Average staining intensities for heparin-binding EGF-like growth factor (HB-EGF) for each subgroup in the tumor and stromal compartment.](IJO-50-06-1947-g03){#f4-ijo-50-06-1947}

![Proposed mechanism of heparin-binding EGF-like growth factor (HB-EGF) expression and macrophage recruitment in cervical cancer.](IJO-50-06-1947-g04){#f5-ijo-50-06-1947}

###### 

Epidermal growth factor receptor (EGFR) ligand and EGFR mRNA expression in cervical cancer.

             mRNA expression[a](#tfn1-ijo-50-06-1947){ref-type="table-fn"}   
  ---------- --------------------------------------------------------------- ----------
  *AREG*     355                                                             149--870
  *BTC*      15                                                              0--43
  *EGF*      −6                                                              −14--3
  *EREG*     15                                                              7--27
  *HB-EGF*   233                                                             145--461
  *TGFα*     145                                                             99--196
  *EGFR*     63                                                              37--94

Normalized mRNA expression was previously determined using expression array analysis of 32 frozen cervical cancer specimens, as described in Materials and methods. AREG, amphiregulin; BTC, β-cellulin; EGF, epidermal growth factor; EREG, epiregulin; HB-EGF, heparin-binding EGF-like growth factor; TGFα, transforming growth factor a; EGFR, epidermal growth factor receptor.

###### 

Tumor and stromal protein expression of HB-EGF, AREG and TGFα in cervical cancer patients.

                N[a](#tfn2-ijo-50-06-1947){ref-type="table-fn"} (%)
  ------------- -----------------------------------------------------
  AREG          
   Tumor        
     Negative   --
     Weak       13 (36)
     Moderate   11 (31)
     Strong     12 (33)
   Stroma       
     Negative   9 (25)
    Positive    27 (75)
  HB-EGF        
   Tumor        
   Negative     --
     Weak       8 (22)
     Moderate   18 (50)
     Strong     10 (28)
   Stroma       
     Negative   12 (33)
     Positive   24 (67)
  TGFα          
   Tumor        
     Negative   --
     Weak       19 (53)
     Moderate   10 (28)
     Strong     7 (19)
   Stroma       
     Negative   10 (28)
     Positive   26 (72)\\

Total number of 36 formalin-fixed, paraffin-embedded cervical cancer tissue samples. AREG, amphiregulin; HB-EGF, heparinbinding EGF-like growth factor; TGFα, transforming growth factor-α.

###### 

Correlations between protein expression of epidermal growth factor receptor (EGFR), EGFR ligands and tumor associated macrophages.

             EGFR expression   
  ---------- ----------------- ---------
  AREG                         
   Tumor     0.11              0.521
   Stromal   0.15              0.392
  HB-EGF                       
   Tumor     0.33              0.049
   Stromal   0.58              \<0.001
  TGFα                         
   Tumor     −0.06             0.751
   Stromal   −0.02             0.927
  TAM                          
   Tumor     0.43              0.009
   Stromal   0.56              \<0.001

ϱ, Spearman\'s correlation coefficient. TAM, tumor associated macrophages; EGFR, epidermal growth factor receptor; AREG, amphiregulin; HB-EGF, heparin-binding EGF-like growth factor; TGFα, transforming growth factor-α; TAM, tumor associated macrophages (CD68-positive cells).
